CN105395919B - It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof - Google Patents
It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof Download PDFInfo
- Publication number
- CN105395919B CN105395919B CN201510816925.8A CN201510816925A CN105395919B CN 105395919 B CN105395919 B CN 105395919B CN 201510816925 A CN201510816925 A CN 201510816925A CN 105395919 B CN105395919 B CN 105395919B
- Authority
- CN
- China
- Prior art keywords
- extract
- black fungus
- effect
- composition
- reducing blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 64
- 241000233866 Fungi Species 0.000 title claims abstract description 60
- 230000000694 effects Effects 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 210000004369 blood Anatomy 0.000 title claims abstract description 44
- 239000008280 blood Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 28
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 22
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 22
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 18
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 18
- 229940010454 licorice Drugs 0.000 claims abstract description 18
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 17
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 12
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 10
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 10
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 10
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 10
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 10
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 10
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 10
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 10
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 10
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 10
- -1 Filtering Substances 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 235000011201 Ginkgo Nutrition 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000009429 Ginkgo biloba extract Substances 0.000 claims description 4
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 4
- 229940068052 ginkgo biloba extract Drugs 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 241000233948 Typha Species 0.000 claims 3
- 240000000171 Crataegus monogyna Species 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 22
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 10
- 210000002966 serum Anatomy 0.000 abstract description 9
- 230000000055 hyoplipidemic effect Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 239000003053 toxin Substances 0.000 abstract description 4
- 231100000765 toxin Toxicity 0.000 abstract description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 230000000975 bioactive effect Effects 0.000 abstract description 2
- 231100000167 toxic agent Toxicity 0.000 abstract description 2
- 239000003440 toxic substance Substances 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 14
- 230000006870 function Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 241001092040 Crataegus Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229930003944 flavone Natural products 0.000 description 8
- 235000011949 flavones Nutrition 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 6
- 240000001398 Typha domingensis Species 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229960004844 lovastatin Drugs 0.000 description 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 150000002213 flavones Chemical class 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- 235000007586 terpenes Nutrition 0.000 description 3
- 239000008802 xuezhikang Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- YXHVCZZLWZYHSA-FPLPWBNLSA-N Ginkgoic acid Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-FPLPWBNLSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- MKDKGLNKTMDNHY-WXUKJITCSA-N (e)-n,5-dihydroxy-n-[3-[5-[3-[hydroxy-[(e)-5-hydroxy-3-methylpent-2-enoyl]amino]propyl]-3,6-dioxopiperazin-2-yl]propyl]-3-methylpent-2-enamide Chemical compound OCCC(/C)=C/C(=O)N(O)CCCC1NC(=O)C(CCCN(O)C(=O)\C=C(/C)CCO)NC1=O MKDKGLNKTMDNHY-WXUKJITCSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000221377 Auricularia Species 0.000 description 1
- 244000028550 Auricularia auricula Species 0.000 description 1
- 235000000023 Auricularia auricula Nutrition 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229920001875 Ebonite Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000218791 Ginkgoaceae Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000134857 Typha capensis Species 0.000 description 1
- 241000233945 Typhaceae Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- CQIUKKVOEOPUDV-UHFFFAOYSA-N citrinine Natural products OC1=C(C(O)=O)C(=O)C(C)=C2C(C)C(C)OC=C21 CQIUKKVOEOPUDV-UHFFFAOYSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 238000011629 hyperlipidemia animal model Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229930185723 monacolin Natural products 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of containing black fungus extract, the composition with effect for reducing blood fat and preparation method thereof, and the composition consists of the following compositions: 400~1100mg of Blackfungus polyhexose, 35~100mg of black fungus melanin, 95~350mg of Red Yeast Rice P.E, 75~180mg of ginkgo biloba p.e, 55~170mg of haw thorn extract, 55~170mg of Pollen Tyjphae extract, 70~170mg of licorice.Composition is using a variety of bioactive substances with hypolipemic function such as black fungus extract, Red Yeast Rice P.E, ginkgo biloba p.e, haw thorn extract, Pollen Tyjphae extracts in the present invention, enhance lipid-lowering effect, and the licorice with detoxication and toxicant eliminating function function is increased as composition, have the effect of synergistic, attenuation toxin expelling.There is the effect of apparent concertedness in terms of reducing serum total cholesterol, serum triglyceride and low density lipoprotein cholesterol, have a clear superiority in terms of reducing side effect.
Description
Technical field
The present invention relates to a kind of composition and preparation method thereof with effect for reducing blood fat.
Background technique
Hyperlipemia seriously threatens human health.Hyperlipemia can directly result in cerebral infarction, thromboangiitis, obesity
The cardiovascular and cerebrovascular diseases such as disease, atherosclerosis, fatty liver, cholelithiasis and atherosclerosis coronary cardiopathy,
And cardiovascular and cerebrovascular disease is one of human maximum cause of the death, cardiovascular and cerebrovascular diseases are died of there are about 12,000,000 people every year in the whole world, therefore high in fat
The prevention and treatment of mass formed by blood stasis are most important.At present to the treatment of hyperlipidemia based on Western medicine, side effect is big, therefore it is aobvious to develop curative effect
It writes, the food aimed at prevention or drug that side effect is low have a very important significance.
Complicated component in compound preparation for reducing blood fat more or less has certain side effect.Therefore developing really has drop blood
Rouge effect and the health care product having no toxic side effect or drug have a very important significance and preferable application prospect.
Black fungus is the dietotherapeutic fungi of Eumycota Basidiomycetes Auriculariale Auriculariaceae Auricularia, contains polysaccharide, black
The a variety of active ingredients such as element.Traditional medicine is recorded, and black fungus has " mild-natured, sweet in flavor ", " QI invigorating is not hungry, strong will of making light of one's life by commiting suicide ", " clearing lung-heat
The effect of moistening lung ", " relieving the five internal organs, toxin expelling gas ".Modern medicine study proves that black fungus, which has, to be improved immunity, anti-aging, resists
Cancer, anti-radiation, antithrombus formation, reducing blood lipid, hypoglycemic, promotion digestion function of stomach and intestine and other effects.No matter black fungus is in disease
Prevent, treat or daily health caring in terms of, all highlight that its is original, is difficult to many effects substituted.Black fungus has drop blood
The active mechanism of rouge is that black fungus can enhance immunity of organisms, adjusts immune function, each organ is normal in maintenance human body
Running improves the activity for participating in enzyme, the normal circulation of liver and gallbladder is promoted to act on.Various composition in blood lipid is made to reach normal shape in this way
State guarantees human health to reduce the accumulating amount of blood lipid in blood.
The hypolipidemic activity composition Study of black fungus focuses primarily upon polysaccharide at present, and extracts for Blackfungus polyhexose normal
The shortcomings that advising aqueous extraction-alcohol precipitation technology is as follows: 1. yield is lower, and higher cost, and Blackfungus polyhexose extract yield is generally 3~
5%, and mostly laboratory stage, higher cost, it is difficult to amplification production.2. since high temperature leads to the drop blood of effective component when extracting
Rouge activity reduces, and limits its extensive use.
Summary of the invention
Contain black fungus extract, the composition with effect for reducing blood fat and its preparation the object of the present invention is to provide a kind of
Method, the composition contain black fungus extract, red yeast rice rice extracts, ginkgo biloba p.e, haw thorn extract, cattail pollen and extract
Object, licorice have effect for reducing blood fat, and its lipid-lowering effect is significantly better than and black fungus extract, red yeast rice is used alone
Extract, ginkgo biloba p.e, haw thorn extract or licorice have the effect of synergistic, Synergistic attenuation.
The purpose of the present invention is what is be achieved through the following technical solutions:
It is a kind of containing black fungus extract, with the composition of effect for reducing blood fat, consist of the following compositions: Blackfungus polyhexose
400~1100mg, 35~100mg of black fungus melanin, 95~350mg of Red Yeast Rice P.E, 75~180mg of ginkgo biloba p.e,
55~170mg of haw thorn extract, 55~170mg of Pollen Tyjphae extract, 70~170mg of licorice.
The preparation method of the above-mentioned composition containing black fungus extract, with effect for reducing blood fat, comprising the following steps:
(1) black fungus is crushed, is stirred evenly with the deionized water of 30~60 times of volumes, place 1~3h, room temperature is using high
Pressure differential method (solution is forced into 1.0~1.5Mpa, and rapid discharge is to normal pressure state in 0.1~0.3s) extracts 1~3 time, filtering,
Filter vacuum is concentrated under reduced pressure, and dry, pulverize to get Blackfungus polyhexose extract;The sodium hydroxide of 2~5 times of volumes is added in filter residue
It is 10.0~11.0 that solution, which adjusts solution ph, stands 1~2h, filtering, it is 3.0~3.5 that supernatant hydrochloric acid, which adjusts pH value, quiet
1~2h is set, is filtered, pellet frozen dry, pulverize, and obtain black fungus melanin.
(2) ginkgo leaf, hawthorn and cattail pollen prepare extract according to following extraction process: raw material crushes, with 10~20 times
It is extracted 2~3 times under 200~500W of ethanol solution ultrasonic wave that volume fraction is 50~95%, 0.5~1.0h, merging mention every time
Liquid is taken, is filtered, filtrate recycling ethanol, concentration dry, pulverize to get alcohol extracting thing.
(3) the cholamine solution (0.1% ammonium hydroxide, 25% ethyl alcohol) of 6~20 times of volumes is added in Radix Glycyrrhizae in 70~90 DEG C of temperature
Degree is lower to carry out 1~2h of refluxing extraction, filters, drying crushes to get licorice.
(4) red yeast rice crushes, using 60~85% ethanol solution of 15~25 times of volumes, under 200~500W of ultrasonic wave
It extracts 2~3 times, 0.5~1.0h, combined extract, filtering, filtrate recycling ethanol, concentration dry, pulverize to get alcohol extracting every time
Take object.
(5) Blackfungus polyhexose, black fungus melanin, haw thorn extract, ginkgo biloba extract, licorice, cattail pollen are mentioned
Take object and Red Yeast Rice P.E to mix to get containing black fungus extract, with the composition of effect for reducing blood fat.
In the present invention, the black fungus raw material carries out autumn in Heilongjiang Province, Ya Buli area, Shangzhi City using black 29 kind
The effect of cultivating the black fungus fructification produced, finding the raw material by comparative analysis ingredient such as Blackfungus polyhexose and melanin contain
Black fungus of the amount than other area productions is high.
In the present invention, Blackfungus polyhexose content 30~40% (after polysaccharide solution ultrafiltration, is used in the black fungus extract
Phenol sulfuric acid procedure measurement), melanin content 3%.
In the present invention, the purity of the Blackfungus polyhexose and melanin is 30~40%.
In the present invention, in the Red Yeast Rice P.E effective component Monacolin-K (Lovastatin) content reach 1.8% with
Upper (HPLC method), wherein open loop (acid) Monacolin-K content accounts for 85% or more.
In the present invention, GINKGO BILOBA EXTRACT >=30% (HPLC method), Total Terpene Lactones >=8% in the ginkgo biloba p.e
(HPLC method), ginkgoic acid≤3ppm.The assay of total flavonoids is referring to " Chinese Pharmacopoeia " ginkgo biloba p.e method, composition
Middle general flavone content uses high-pressure liquid phase chromatogram therapy determining.
In the present invention, 15% or more glycyrrhizic acid content in the licorice, triterpenes and flavone compound always contain
Amount 20~30%, Polyhydroxy phenol content 5~35%.
In the present invention, general flavone content 20~25% (HPLC method) in the Pollen Tyjphae extract.
In the present invention, general flavone content 3~25% in the haw thorn extract.
In the present invention, the grinding particle size of the black fungus is 150~240 mesh, 200 mesh of optimal granularity.
In the present invention, the ginkgo leaf, hawthorn, cattail pollen and red yeast rice grinding particle size be 100~150 mesh.
Red yeast rice is generated by Fermentation Condition of Monascus spp, and Fermentation Condition of Monascus spp can produce a variety of metabolites, mainly there is monascorubin, enzyme
Class active material, material for lowering blood pressure etc..Applying for Red Yeast Rice P.E is with a long history in China, be used to make wine from ancient times, makes vinegar, is roasting
The food colorings such as duck.Modern medicine discovery red yeast rice has the function of reducing cholesterol.Due to playing effect for reducing blood fat in red yeast rice
Effective component is not only Monacolin class (Lovastatin), further includes carboxylic acid Lovastatin, ergosterol, pigment, γ-
Aminobutyric acid, Dimerumicacid etc. and other compositions, since the other compositions of Red Yeast Rice P.E are also playing its unique work
With, thus Red Yeast Rice P.E reducing blood lipid, anticancer and anti-oxidant aspect function and effect may be greater than Lovastatin is applied alone
Effect.
Ginkgo leaf is the dried leaf of Ginkgoaceae plant Ginkgo biloba, has that promoting blood circulationization is tired, removes obstruction in channels to relieve pain and other effects, clinically more
For cardiovascular and cerebrovascular disease.Up to the present, isolated flavones, terpene lactones, organic acid, amino acid, polysaccharide in ginkgo leaf
Equal ingredients.General flavone and terpene lactone have clear bioactivity as the characteristic chemical constituent in ginkgo leaf.
Hawthorn is rosaceous plant, containing various bioactivators, such as triterpenic acid, flavones, wherein flavones ingredient
There is decompression, reducing blood lipid, increase the pharmacological actions such as coronary flow, heart tonifying, arrhythmia.According to the pharmacological action of hawthorn, now
Have many hawthorn and hawthorn compound preparation is applied to clinic to treat the hearts such as hyperlipemia, coronary heart diseases and angina pectoris, arrhythmia cordis
Vascular diseases, China's Hawthorn Resources are abundant, low in cost, there is good value of exploiting and utilizing.
Cattail pollen is the dry pollen of Typhaceae plant or congener, has the function of hemostasis, stagnation resolvation, treating stranguria, for the heart
The prevention and treatment of cranial vascular disease.
Licorice has prevention and treatment hyperlipidemia, antiviral, prevention and treatment AIDS, anticancer, enhancing Culture in vitro and subtracts
Malicious toxin expelling effect, the main effective ingredient of Radix Glycyrrhizae are glycyrrhizic acid and glucoside member enoxolone.
The present invention has the advantage that
1) Thick many candies extract yield is up to 12~18% or more in black fungus extract, 30% or more purity, and mentions for low temperature
It takes, has been sufficiently reserved bioactivity;3% or more melanin recovery rate, 40% or more purity.
2) present invention in composition using black fungus extract, Red Yeast Rice P.E, ginkgo biloba p.e, haw thorn extract,
A variety of bioactive substances with hypolipemic function such as Pollen Tyjphae extract, enhance lipid-lowering effect, and increase and have
The licorice of detoxication and toxicant eliminating function function has the effect of synergistic, attenuation toxin expelling as composition.Reducing the total gallbladder of serum
There is the effects of apparent concertedness in terms of sterol, serum triglyceride and low density lipoprotein cholesterol, are reducing side effect
Aspect has a clear superiority.According to reducing blood lipid test operation in the test of national function of health food, the results showed that composition is dropping
It is significantly better than in terms of blood lipid effect and black fungus extract, Red Yeast Rice P.E or ginkgo biloba p.e is used alone.
3) black fungus extract extracts separation concentration technique using efficient high-pressure difference low temperature continous way, and whole process uses physics side
Formula, low temperature extract, and recovery rate is high and realizes that the ecosystem of active constituent retains.Height pressure difference extractive technique makes cell moment quick-fried
Split, come into full contact with solvent, be extracted in black fungus 85% or more polysaccharide, make polysaccharide yield reach 12~
18%.
4) the composition proves there is auxiliary effect for reducing blood fat through animal experiment and human experiment result, can be applied to it is middle at
Medicine, health food or food reduce cholesterol and blood viscosity, promote the microcirculation of cardiovascular and cerebrovascular, improve body fat metabolism,
Enhance immunity of organisms, there is auxiliary lipid-lowering function.
Specific embodiment
Below with reference to embodiment, further description of the technical solution of the present invention, and however, it is not limited to this, all right
Technical solution of the present invention is modified or replaced equivalently, and without departing from the spirit and scope of the technical solution of the present invention, should all be contained
Lid is within the protection scope of the present invention.
Embodiment 1:
It is provided in this embodiment to be consisted of the following compositions containing black fungus extract, the composition with effect for reducing blood fat:
Black fungus extract (the melanin 70mg that Blackfungus polyhexose 550mg and purity including purity 40% are 40%), red yeast rice extract
Object 330mg, ginkgo biloba p.e 90mg, haw thorn extract 150mg, Pollen Tyjphae extract 150mg, licorice 150mg.
Embodiment 2:
It is provided in this embodiment to be consisted of the following compositions containing black fungus extract, the composition with effect for reducing blood fat:
Black fungus extract (the melanin 90mg that Blackfungus polyhexose 1000mg and purity including purity 30% are 40%), red yeast rice extract
Object 110mg, ginkgo biloba p.e 160mg, haw thorn extract 80mg, Pollen Tyjphae extract 80mg, licorice 80mg.
Embodiment 3:
It is provided in this embodiment to be consisted of the following compositions containing black fungus extract, the composition with effect for reducing blood fat:
Black fungus extract (the melanin 50mg that Blackfungus polyhexose 800mg and purity including purity 40% are 30%), red yeast rice extract
Object 250mg, ginkgo biloba p.e 120mg, haw thorn extract 100mg, Pollen Tyjphae extract 100mg, licorice 100mg.This
For 1 person-time of consumption per day (1.52g), divides 2 times and take.
Preparation method:
(1) black fungus powder is broken to 200 mesh, is stirred evenly with the deionized water of 40 times of volumes, place 2h, room temperature is using high
Pressure differential method (solution is forced into 1.0Mpa, and rapid discharge is to normal pressure state in 0.1s) extracts 2 times, filtering, filter vacuum concentration,
It dry, pulverize to get Blackfungus polyhexose extract;The sodium hydroxide solution that 4 times of volumes are added in filter residue adjusts solution ph
10.5,1.5h, filtering are stood, it is 3.2 that supernatant hydrochloric acid, which adjusts pH value, stands 1.5h, filtering, and pellet frozen dry, pulverize,
Obtain black fungus melanin.
(2) ginkgo leaf, hawthorn and cattail pollen prepare extract according to following extraction process: raw material is crushed to 100 mesh, with 15
Is extracted 3 times, each 0.5h under the ethanol solution ultrasonic wave 300W that times volume fraction is 60%, combined extract, filtering, filtrate time
Ethyl alcohol is received, concentration dry, pulverize to get alcohol extracting thing.
(3) the cholamine solution (0.1% ammonium hydroxide, 25% ethyl alcohol) that 10 times of volumes are added in Radix Glycyrrhizae carries out at a temperature of 80 DEG C
Refluxing extraction 1.5h is filtered, and drying crushes to get licorice.
(4) Red Yeast Rice P.E preparation process are as follows: 5 constant virtues organic rice, boiling, cooling, is inoculated with purple leaf Monascus, day at immersion
Right cultivation and fermentation, production red yeast rice, are crushed to 100 mesh, using 80% ethanol solution of 20 times of volumes, mention under ultrasonic wave 500W
It takes 2 times, each 1.0h, combined extract, filters, filtrate recycling ethanol, concentration dry, pulverize to get alcohol extracting thing.This work
The content of the functional red yeast rice effective component of skill production is more clear, and effect is more precisely.It without citrinin, has no toxic side effect, reduces liver
Dirty burden, absorption are easier, and effect is more brilliant.
(5) Blackfungus polyhexose, black fungus melanin, haw thorn extract, ginkgo biloba extract, licorice, cattail pollen are mentioned
Object and Red Yeast Rice P.E are taken, prepares hard capsule, or be mixed together with pharmaceutic adjuvant and oral preparation, ebonite are made according to a conventional method
One of capsule, soft capsule, tablet, granule, powder, pill, tea bag, liquid beverage are a variety of, can be in preparation reducing blood lipid
It is applied in drug, health food.
Zoopery:
Experimental method: it is provided using SD rat by Shanghai Slac Experimental Animal Co., Ltd., production licence number
For SCXK (Shanghai) 2012-0002;Weight 200-250g, male is random to be grouped, respectively normal group, model group, positive control drug
Effects of Xuezhikang 0.2gkg-1Group and black fungus extractive compound preparation 0.135,0.27,0.54gkg-1Basic, normal, high 3 agent
Amount group, every group 10.In addition to normal group is given drinking water, each group rat is fed with high lipid food (Nantong Te Luofei feed),
3 times a day, continuous 3 weeks.For model group compared with normal group, TC and LDL-C are significantly raised, there is significant difference (P < 0.01),
Show that high lipid food makes the success of Rat Experimental hyperlipidemia animal model.Qualified rat is examined to start to test: gastric infusion, often
Day, in addition to Normal group, each group rat continues to feed with high lipid food.Each administration group gives black fungus extractive compound preparation
(dosage is respectively 0.135,0.27,0.54gkg to low, middle and high dose groups-1), gastric infusion capacity 20mLkg-1.Positive drug
Effects of Xuezhikang 0.2gkg-1, gastric infusion capacity 10mLkg-1.Continuous 8 weeks.The blood sampling of each group rat, separates serum, using glycerol
Three esters, total cholesterol, low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) testing cassete (Beijing
Bei Huatai clinical reagent Co., Ltd) each content of measurement.
Experimental result: compared with model group, TG, TC and LDL-C level, difference can be effectively reduced in positive control Effects of Xuezhikang group
There is significant (P < 0.01);Each dosage group serum High Density Lipoprotein Cholesterol (HDL-C) is not significantly lower than model comparison
Group;Compound Jew ' s-ear extract low, middle and high dose groups can be substantially reduced TG, TC and LDL-C level, except low dose group reduction is low
Except density lipoprotein-cholesterol (LDL-C) difference more significant (P < 0.05), other each groups and model group comparing difference are extremely aobvious
It writes (P < 0.01), and each group HDL-C level and model group difference is not significant.Each experimental group blood lipid level testing result such as 1 institute of table
Show.
1 black fungus compound preparation of table to hyperlipidemia rats blood lipid level influence ()mmol·L-1
Note: compared with blank groupaP < 0.01,bP<0.05;Compared with model group,cP < 0.01,dP<0.05。
Composition has the function of reducing serum triglyceride, total cholesterol, low-density lipoprotein, and makes high density lipoprotein level
White cholesterol slightly improves, and has significant hypolipemic function, and lipid-lowering effect is better than being applied alone any a kind of extraction in composition
The lipid-lowering effect (being shown in Table 2) of object.
2 black fungus compound preparation of table and single preparations of ephedrine to hyperlipidemia rats blood lipid level influence ()
mmol·L-1
Note: compared with blank groupaP < 0.01,bP<0.05;Compared with model group,cP < 0.01,dP<0.05。
Human feeding trial:
To examine therapeutic effect of the invention, 200 hyperlipemic patients are chosen, selected patient meets hyperlipidemia diagnosis
Standard.Wherein male 75, women 75, the age 40~63 years old, average age 48 years old.4 groups are randomly divided into, every group of 50 people.The
One group is treated with composition prepared by embodiment 1;Second group is treated with composition prepared by embodiment 2;Third group embodiment 3
The composition of preparation is treated;4th group is given placebo for blank control group.Course for the treatment of 90d distinguishes empty stomach 12h before and after treatment
TC, TG, LDL-C, HDL-C, the heart, Liver and kidney function and blood, urine, feces routine etc. are measured in early morning venous blood samples afterwards.In experiment opening
Chest X-rays, electrocardiogram, abdominal B-scan ultrasonography inspection are carried out before beginning.It the results are shown in Table 3.
Indices determine as follows:
(1) effectively: TC reduces > 10%;TG reduces > 15%;HDL-C rising > 0.104mmol/L.
(2) invalid: not up to effective standard person.
3 human body of table foretastes test group test result (n=50)
Conventional, the Liver and kidney function inspection by the inspection and blood, urine, feces that carry out blood lipids index to each group individual after test
Result carry out analysis find each embodiment total effective rate be 96.0% or more, rate of side effects and half a year recurrence rate are 0.
Liver and kidney function inspection result shows that test group hepatic and renal function is also more healthy than the physical signs before taking composition, overall performance
Composition has the outstanding feature of Synergy and attenuation.
Conclusion:
The present invention has preferable effect to the generation and treatment of hyperlipidemia.
By animal experiments show that: 1) model control group and blank control group compare, serum total cholesterol or low density lipoprotein
Protein cholesterol increases, and difference has conspicuousness, and decision model is set up;2) each dosage group is compared with model control group, middle and high dosage
Group serum total cholesterol, serum triglyceride, low density lipoprotein cholesterol reduce, and difference has conspicuousness, and each dosage group
Serum High Density Lipoprotein Cholesterol is not significantly lower than model control group, shows that the given the test agent auxiliary lipid-lowering function animal is real
Test the result positive.
Shown by human feeding trial inspection result: 1) each embodiment total effective rate of composition is 96.0% or more, secondary
It reacts incidence and half a year recurrence rate is 0;2) inspection results such as Human Physiology index and Liver and kidney function show composition entirety
It is demonstrated by the outstanding feature with Synergy and attenuation.
Claims (5)
1. a kind of preparation method of the composition containing black fungus extract, with effect for reducing blood fat, containing black fungus extract,
Composition with effect for reducing blood fat, consists of the following compositions: 400~1100mg of Blackfungus polyhexose, black fungus melanin 35~
100mg, 95~350mg of Red Yeast Rice P.E, 75~180mg of ginkgo biloba p.e, 55~170mg of haw thorn extract, cattail pollen are extracted
55~170mg of object, 70~170mg of licorice;
It is characterized in that steps are as follows for the preparation method:
(1) black fungus is crushed, is stirred evenly with the deionized water of 30~60 times of volumes, place 1~3h, room temperature uses High Pressure Difference
Method is extracted 1~3 time, and filtering, filter vacuum is concentrated under reduced pressure, and dry, pulverize to get Blackfungus polyhexose extract;Filter residue addition 2~
The sodium hydroxide solution adjustment solution ph of 5 times of volumes is 10.0~11.0, stands 1~2h, filtering, supernatant is adjusted with hydrochloric acid
PH value is 3.0~3.5, stands 1~2h, filtering, and pellet frozen dry, pulverize, and obtains black fungus melanin;
(2) ginkgo leaf, hawthorn and cattail pollen prepare extract according to following extraction process: raw material crushes, with 10~20 times of volumes
2~3 times are extracted under 200~500W of ethanol solution ultrasonic wave that score is 50~95%, every time 0.5~1.0h, combined extract,
Filtering, filtrate recycling ethanol, concentration dry, pulverize to get alcohol extracting thing;
(3) the cholamine solution that 6~20 times of volumes are added in Radix Glycyrrhizae carries out 1~2h of refluxing extraction, mistake at a temperature of 70~90 DEG C
Filter, drying crush to get licorice;
(4) red yeast rice crushes, and using 60~85% ethanol solution, extracts 2~3 times under 200~500W of ultrasonic wave, and every time 0.5
~1.0h, combined extract, filtering, filtrate recycling ethanol, concentration dry, pulverize to get alcohol extracting thing;
(5) by Blackfungus polyhexose, black fungus melanin, haw thorn extract, ginkgo biloba extract, licorice, Pollen Tyjphae extract
With Red Yeast Rice P.E mix to get containing black fungus extract, with the composition of effect for reducing blood fat.
2. the preparation method of the composition according to claim 1 containing black fungus extract, with effect for reducing blood fat,
It is characterized in that the black fungus is the black fungus fructification that black 29 kind carries out autumn culture.
3. the preparation method of the composition according to claim 1 containing black fungus extract, with effect for reducing blood fat,
The purity for being characterized in that the Blackfungus polyhexose and melanin is 30~40%.
4. the preparation method of the composition according to claim 1 containing black fungus extract, with effect for reducing blood fat,
The grinding particle size for being characterized in that the black fungus is 150~240 mesh.
5. the preparation method of the composition according to claim 1 containing black fungus extract, with effect for reducing blood fat,
The grinding particle size for being characterized in that the ginkgo leaf, hawthorn, cattail pollen and red yeast rice is 100~150 mesh.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510816925.8A CN105395919B (en) | 2015-11-23 | 2015-11-23 | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510816925.8A CN105395919B (en) | 2015-11-23 | 2015-11-23 | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105395919A CN105395919A (en) | 2016-03-16 |
CN105395919B true CN105395919B (en) | 2019-03-19 |
Family
ID=55461907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510816925.8A Active CN105395919B (en) | 2015-11-23 | 2015-11-23 | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105395919B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107319555A (en) * | 2017-07-21 | 2017-11-07 | 韩希典 | A kind of food of reducing blood lipid |
CN108743632B (en) * | 2018-04-27 | 2021-07-27 | 浙江工业大学 | Method for removing ginkgolic acid in ginkgo by ultrasonic assistance |
CN110643655B (en) * | 2019-10-23 | 2022-04-26 | 河北科技大学 | Hawthorn flavone chelated sugar and preparation method and application thereof |
CN111096447A (en) * | 2019-12-30 | 2020-05-05 | 广州泽力医药科技有限公司 | Tremella pulp, preparation method and application thereof, thickener and preparation method thereof |
CN113694105B (en) * | 2021-10-11 | 2023-01-24 | 于洪林 | Composition with blood fat reducing function and application thereof |
CN115137069A (en) * | 2022-09-06 | 2022-10-04 | 山东向日葵生物工程有限公司 | Lactobacillus delbrueckii subspecies bulgaricus SF-L-18 fermented product and preparation method and application thereof |
CN116098981A (en) * | 2023-01-10 | 2023-05-12 | 辽宁农业职业技术学院 | Medicinal and edible traditional Chinese medicine composition for reducing blood fat and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104187678A (en) * | 2014-09-11 | 2014-12-10 | 浙江方格药业有限公司 | Health composition for reducing blood fat and production method of health composition |
-
2015
- 2015-11-23 CN CN201510816925.8A patent/CN105395919B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104187678A (en) * | 2014-09-11 | 2014-12-10 | 浙江方格药业有限公司 | Health composition for reducing blood fat and production method of health composition |
Non-Patent Citations (2)
Title |
---|
活血降脂汤治疗高脂血症46例小结;郭志华;《湖南中医杂志》;19960331;第12卷(第2期);第6页,尤其是第6页左栏第3段 * |
银曲胶囊调节血脂药效学研究;张朝波等;《安徽医药》;20110430;第15卷(第4期);第421-423页,尤其是第421页摘要和左栏第1段 * |
Also Published As
Publication number | Publication date |
---|---|
CN105395919A (en) | 2016-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105395919B (en) | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof | |
CN102697035A (en) | Cordyceps anti-aging pellet | |
CN108042627B (en) | Composition for treating hyperuricemia and preparation method and application thereof | |
CN102038745B (en) | Hypolipidemic traditional Chinese medicine | |
CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
CN103142916B (en) | Medicament for preventing and treating senile dementia and preparation method thereof | |
KR20040002742A (en) | A ginseng preparation using vinegar and process for thereof | |
CN103566282B (en) | A kind of Traditional Chinese medicine composition with anti-tumor effect and preparation method | |
CN108210547A (en) | The preparation method and its preparation of a kind of Extracts from Leaves of Phyllanthus emblica L and anti-Ai Yingyong | |
CN104857034A (en) | Functional food for preventing and treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
CN103610048B (en) | To chemical damage health food having assistant protection function and preparation method thereof | |
KR20130074121A (en) | Ginseng prosapogenin high concentration containing sanchi ginseng preparation using sonication and process for thereof | |
CN110051817A (en) | A kind of Chinese traditional medicine composition and its application reducing uric acid | |
CN109010579A (en) | A kind of antioxidant and anti-aging Chinese traditional compound medicine and preparation method thereof | |
JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
CN107375509A (en) | It is a kind of to be used to improve immunity, the health food of pre- anti-cancer | |
CN104288566B (en) | Traditional Chinese medicine composition for reducing cholesterol and/or reducing blood lipids as well as preparation method and application of traditional Chinese medicine composition | |
KR101381507B1 (en) | A Red ginseng using microwave and process for thereof | |
CN111991436A (en) | Application of atractylis lancea aqueous extract in preparation of medicine for preventing, relieving and/or treating hyperuricemia | |
CN105193993B (en) | A kind of Chinese medicine composition with blood fat reducing function and preparation method thereof and purposes | |
CN104256618A (en) | Food, health care product or medicine composition with blood sugar reduction function | |
CN108478701A (en) | A kind of lozenge of strengthen immunity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |